CBI

Clal Biotechnology Industries – a leading Israeli life sciences investment company

about cbi

Clal Biotechnology Industries is a leading Israeli life sciences investment company traded on the Tel Aviv Stock Exchange (TASE: CBI). CBI supports life science ventures by identifying and empowering science-backed projects and proactively guiding them to fruition

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Gamida Cell's lead product, omidubicel, has recently successfully completed a phase III clinical trial in hematological malignancies.
+

Elicio

Elicio develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with many potential applications in cancer and infectious diseases.
+

Cadent Therapeutics

Cadent Therapeutics is developing innovative drugs for neurological and psychiatric disorders. This company has been recently acquired by Novartis.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company discovering and developing small molecule inhibitors of Factor XIa, which offer the potential of thrombosis prevention without the bleeding liabilities.
+

Biokine

Biokine Therapeutics is developing novel therapeutics to treat cancer. It's lead product, motixafortide (formerly BL-8040), is licensed to BiolineRx and is currently in phase III clinical development.

See complete portfolio

Press Releases

2021

29

Jul

MediWound: Positive Outcome in EscharEx®’s Phase 2 Trial Interim Assessment
26

Jul

MediWound: Initiation of a Phase I/II Study of MW005 in the Treatment of Basal Cell Carcinoma
21

Jul

Cactus SPAC: Filing of a Nasdaq Prospectus (S-1) Prior to an IPO
20

Jul

MediWound: Positive Results from Phase 3 Pediatric Study of NexoBrid in Severe Burns
04

Jul

Capital Point Acquires Part of CBI’s Holdings in eXIthera
30

Jun

MediWound: Complete Response Letter from the FDA for NexoBrid’s BLA

Read all Press Releases